Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Clinical trial NCT04318938 · COMPLETED
Trial details
- NCT number
- NCT04318938
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-30
- Primary completion
- 2026-05-30
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.